Showing 1220 – 1230 of 1299 results
-
APi Group Corporation Initiation
William Blair initiated research coverage of APi Group Corporation (APG $37.65), the global leader in life safety services, with a total addressable market that is estimated to exceed $150 billion.
-
Vigil Neuroscience Inc Initiation
William Blair initiated research coverage of Vigil Neuroscience, Inc. (VIGL $2.47), a clinical-stage biopharma focused on developing microglial-targeting therapeutics by leveraging genetic insights into degenerative disorders of the central nervous system (CNS).
-
Shift4 Payments Inc Initiation
William Blair initiated research coverage of Shift4 Payments, Inc. (FOUR $83.10), a leading merchant acquirer or payment service provider (PSP). Shift4 operates four complementary businesses: a proprietary gateway, a leading venue payments and ticketing business, an emerging software-enabled POS, and a cross-border e-commerce acquirer.
-
Gilat Satellite Networks Ltd Initiation
William Blair initiated research coverage of Gilat Satellite Networks Ltd. (GILT $4.96), an Israel-based provider of satellite communications infrastructure.
-
AAR Corp Initiation
William Blair initiated research coverage of AAR Corp. (AIR $57.14), a provider of supply chain and maintenance, repair, and overhaul (MRO) services for commercial aviation and government customers.
-
Primo Water Corporation Initiation
William Blair initiated research coverage of Primo Water Corporation (PRMW $27.67), a leading North America–focused pure-play water solutions provider.
-
CARGO Therapeutics Inc Initiation
William Blair initiated research coverage of Cargo Therapeutics, Inc. (CRGX $16.23), a clinical-stage biotech company focused on developing next-generation CAR-T therapies for the treatment of cancer.
-
Alto Neuroscience Inc Initiation
William Blair initiated research coverage of Alto Neuroscience, Inc. (ANRO $13.72), a company focused on developing novel therapies for high-unmet-need indications in psychiatry supported by AI-enabled precision approaches to identify response biomarkers.
-
Keros Therapeutics Inc Initiation
William Blair initiated research coverage of Keros Therapeutics, Inc. (KROS $59.49), a company focused on the development of novel therapies targeting the TGF-β superfamily of cytokines, which play essential roles in the proliferation and differentiation of numerous cell types.
-
First Advantage Corporation Initiation
William Blair initiated research coverage of First Advantage Corporation (FA $15.32), a leading global provider of technology-enabled background screening products.